Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Asthma
In brief
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Key facts
- Study ID
- NCT05398263
- Run by
- AstraZeneca
- People needed
- 125
- Starts
- 2022-08-09
- Expected to finish
- 2025-03-24
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Curicó, Chile
- Research Site — Santiago, Chile
- Research Site — Newport Beach, California, United States
- Research Site — Denver, Colorado, United States
- Research Site — Newark, Delaware, United States
- Research Site — Hialeah, Florida, United States
- Research Site — Miami Lakes, Florida, United States
- Research Site — Lincoln, Nebraska, United States
- Research Site — The Bronx, New York, United States
- Research Site — El Paso, Texas, United States
- Research Site — Kingwood, Texas, United States
- Research Site — Botucatu, Brazil
- Research Site — Curitiba, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — Salvador, Brazil
- Research Site — São Bernardo do Campo, Brazil
- Research Site — São Paulo, Brazil
- Research Site — Sorocaba, Brazil
- Research Site — Ajax, Ontario, Canada
- Research Site — Québec, Quebec, Canada
- Research Site — Santiago, Chile
- Research Site — Santiago, Chile
- Research Site — Santiago, Chile
- Research Site — Chile, Chile
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.